CALT News and Press, Calliditas Therapeutics AB From 04/27/23

2023-04-27 09:17:35 ET Summary Part B portion of Phase 3 NefIgArd trial reveals positive outcomes for nefecon, leading to a reaffirmed buy recommendation for Calliditas. Nefecon demonstrates statistically significant stabilization of eGFR levels in IgAN patients, with consistent b...

Calliditas Therapeutics' 2022 Annual Report Published PR Newswire STOCKHOLM , April 26, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2022 now is available at the company's websi...

2023-04-12 06:34:14 ET Summary Calliditas Therapeutics recently reported positive long-term data of Tarpeyo (Nefecon/budesonide) in patients with IgA nephropathy. The results confirmed the previous positive findings from the phase 3 trial and indicate a potential disease-modifying...

NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) ...

2023-04-06 05:40:50 ET Singapore's Health Sciences Authority (HSA) accepted to review Everest Medicines' application seeking approval of Nefecon to treat primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. The company expects to get approval of the...

Calliditas to participate in upcoming investor conferences PR Newswire STOCKHOLM , March 31, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced its management's participation in the following i...

2023-03-13 13:15:19 ET Calliditas Therapeutics ( NASDAQ: CALT ) added 35% on Monday after announcing that its Phase 3 trial for renal disease candidate Nefecon reached the primary endpoint, paving the way for Swedish pharma to seek its full approval. In Dec. 2021, the U....

2023-03-13 12:54:16 ET Gainers: Provention ( PRVB ) +258% . Euda Health ( EUDA ) +41% . Calliditas ( CALT ) +31% . Cipher Mining ( CIFR ) +29% . Caleminder ( CMND ) +26% . Bakkt ( BKKT ) +26% . Hut 8 Mining ( HU...

2023-03-13 10:02:38 ET Gainers: Provention Bio PRVB +248% . Caleminder ( CMND ) +38% . Calliditas Therapeutics ( CALT ) +32% . Euda Health ( EUDA ) +22% . Seagen  ( SGEN ) +15% . Losers: Cingulate CING -28...

2023-03-13 08:54:26 ET Provention Bio PRVB +263% on ~$2.9B acquisition by Sanofi. Calliditas Therapeutics ( CALT ) +29% announces primary endpoint successfully Met in phase 3 NefIgArd trial evaluating Nefecon® in IgA Nephropathy. Caleminder ( CMND ...